Emily Colman

Company

Emily Colman is listed as a founder of RonanRx Inc.. RonanRX is a full-stack pharmaceutical company, starting with personalized peptides and GLP-1s. In our first 10 weeks, we went from having no pharmacy to being licensed in 33 states. Since launch, we’ve grown 50% week over week. We manufacture the medications ourselves, sell directly to patients, and eliminate the layers of middlemen that make prescription drugs more expensive. What makes this possible is AI. Traditional pharmaceutical companies are built to manufacture one drug for millions of people. RonanRX is purpose-built to personalize treatment for each patient: different biology, different response, different dose. Patients come directly to RonanRX or through doctors using our platform. Every patient completes our medical intake, meets with a licensed doctor through our telehealth platform, and receives a personalized prescription when appropriate. From there, we manufacture the medication ourselves and deliver it directly to the patient. Labs, wearables, medical history, treatment response, and other health data feed back into the platform so doctors can continuously refine treatment over time. Before AI, doing this for every patient at scale was impossible. We didn't invent the demand we are seeing. 80 Million people are on a GLP-1 and millions more are using Peptides. We're building a better way to manufacture, personalize, prescribe, and deliver them. Our founders have built and exited multiple companies, raised more than $100M, built a $50M U.S. medical manufacturing business, and spent years developing peptide therapeutics at companies including Eli Lilly and AbbVie. We’re just getting started with peptides and GLP-1s. Next comes hormone therapy and the rest of personalized medicine.

Companies in related industries